sible for inhibition of complement-mediated cell lysis, leads to hemolysis and hemoglobinuria. Interestingly, clonal populations of cells with the PNH genotype and phenotype can be detected in normal individuals using very sensitive flow cytometric and PCR techniques. 3 The abnormal hematopoiesis of PNH may develop after treatment of aplastic anemia with immunosuppressive drugs or after chemotherapy for malignancy. 4 Hematopoietic cells with the PNH phenotype can be identified in cases of aplastic anemia, myelodysplastic syndrome, or leukemia. 5, 6 Affected patients may demonstrate hemolysis, venous thrombosis, and the development of myelodysplastic syndrome or aplastic anemia. Three patients treated with highdose erythropoietin and low-dose corticosteroids demonstrated improvements in hemoglobin and reduction in transfusion requirements. 7 Treatment with the androgen danazol resulted in improvement in hematocrit and eventual cessation of transfusions in four of five cases. 8 Cases of bone marrow transplantation for patients with aplastic anemia, myelodysplastic syndrome, recurrent severe hemolysis, and Budd-Chiari syndrome have been reported. [9] [10] [11] [12] [13] [14] [15] [16] [17] Syngeneic donors with or without pretransplant conditioning have been utilized with variable results. The first reported patient underwent unconditioned PBSC transplantation, which was unsuccessful. A subsequent infusion of syngeneic bone marrow led to engraftment and disease correction. 17 Champlin et al 11 reported four patients who failed to engraft after unconditioned syngeneic BMT. All four received successful second transplants after cyclophosphamide with or without TBI. Kolb et al 10 reported two patients with PNH who underwent syngeneic BMT. One patient with frequent, severe hemolytic episodes underwent unconditioned BMT with no response. A second patient with PNH underwent successful syngeneic BMT after myeloablative conditioning. Myeloablation appears to be necessary for successful engraftment in the majority of patients with syngeneic donors. 9, 16 Endo et al 16 showed that unconditioned syngeneic transplantation led to a transient increase in donor peripheral blood cells with normal expression of GPI-anchored proteins. This patient was asymptomatic after transplantation. At 17 months post-BMT, the percentage of donor cells decreased and was associated with recurrent hemolysis. The gradual increase in abnormal PNH cells suggested that the abnormal stem cells might have a survival advantage. Doukas et al reported successful transplantation of a 24-year-old patient with multiple venous thromboses with syngeneic bone marrow after busulfan and cylcophosphamide conditioning. This patient engrafted and remains free of PNH red cells over 11 years after transplantation.
Several reports describe matched sibling BMT for aplastic anemia, recurrent thromboses, or refractory hemolysis associated with PNH.
12, 13 Bemba et al 13 reported 16 patients transplanted after conditioning with matched sibling donors. Six of these had PNH after severe aplastic anemia while 10 had de novo PNH. Conditioning consisted of cyclophosphamide (150 mg/kg) and thoraco-abdominal irradiation in 15 and cyclophosphamide and 8 Gy TBI in one patient. There were nine survivors, with seven deaths due to infection and/or GVHD. In a report by Kawahara et al 12 six patients were transplanted with matched sibling donors for aplastic complications (n = 4), anemia and hemolysis (n = 1), and hemolysis and thromboses (n = 1) due to PNH. All six patients were long-term survivors. A recent report by Raiola et al 18 describes successful MSD BMT in seven patients with PNH. Saso et al 14 summarized 57 patients reported to the International Bone Marrow Transplant Registry (IBMTR). This experience included 48 matched sibling donors, six unrelated donors, and one haploidentical BMT. Patients were treated with varying conditioning regimens. Thirty-seven of 48 (77%) evaluable MSD recipients had sustained donor engraftment. 34% developed уacute GVHD, while 33% developed chronic GVHD. Overall survival was 56% for the MSD cohort at a median of 44 months after BMT. Causes of death included graft failure, interstitial pneumonitis, infection and GVHD. Strikingly, only 1/7 alternate donor BMT recipients survived. Causes of death for alternate donor recipients included graft failure (n = 2), interstitial pneumonitis (n = 1), organ failure (n = 1), chronic GVHD (n = 1), and new malignancy (n = 1). The overall reported experience for alternate donor BMT for PNH is limited to eight patients with only one survivor. Our series reports three patients undergoing matched unrelated donor allogeneic BMT for PNH. All three patients experienced side-effects that are often associated with transplantation of marrow from matched unrelated donors, yet all are survivors at a median of 3 years after BMT.
Materials and methods

Patients
Patient characteristics are listed in Table 1 . Three patients with PNH and myelodysplastic syndrome (MDS) (n = 2) or severe aplastic anemia (SAA) (n = 1) received BMT between 1995 and 1998 at St Jude Children's Research Hospital. Diagnosis of MDS was made by review of bone marrow aspirates using the FAB classification. 19 Diagnosis of PNH was originally made by sucrose hemolysis and Ham's test in two patients and by flow cytometry to CD55 and CD59 in one patient. Two patients had an original diagnosis of severe aplastic anemia, while one patient had moderate aplastic anemia. Transplant-related toxicity was graded by the Bearman criteria. 
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Severe aplastic anemia
The original diagnosis of severe aplastic anemia occurred at ages 3 and 13 years, respectively, and resulted in treatment with equine anti-thymocyte globulin for two courses.
One of these patients additionally received four courses of corticosteroids, three courses of cyclosporine, and two courses of oxymetholone. The diagnosis of PNH occurred 11 years after treatment with multiple immunosuppressive agents in one patient, while PNH occurred 1.5 years after treatment with ATG in the second patient. The diagnosis of PNH was followed by the development of MDS 10 and 21 months later, respectively.
Moderate aplastic anemia
One patient was diagnosed with moderate AA at age 4 years. This patient initially received no treatment, but was treated with equine ATG and hydrocortisone after evoluation to severe aplastic anemia and PNH 8 years later.
Specifics of BMT
Patient and transplant specifics are given in 35 at the HLA-A locus (n = 1). Pre-transplant conditioning consisted of Ara-C 18 g/m 2 in six divided doses administered every 12 h, cyclophosphamide 45 mg/kg/day ϫ 2 days, fractionated TB1 (14 Gy), Mesna 45 mg/kg/day in five divided doses, and ATG 30 mg/kg/day ϫ 3 days. T cell depletion was performed by treatment of grafts with anti-CD6/CD8 antibodies ϩ complement. 21 Cyclosporine was administered post-BMT as GVHD prophylaxis. Donor chimerism studies were performed by variable nucleotide tandem repeats (VNTR).
Patients received a median of 1. Three patients experienced side-effects that were typical for unrelated donor transplantation. One had two significant complications, hemorrhagic cystitis and hemolytic-uremic syndrome (HUS). Grade III hemorrhagic cystitis occurred 2-3 months post BMT and required cystoscopy and bladder irrigation. Urine cultures for bacterial and viral pathogens were negative. Cytology specimens from the cystoscopy were negative for viral changes. This patient also developed transient HUS responsive to erythropoietin. A second patient developed grade I veno-occlusive disease (VOD) of the liver with a maximum total bilirubin of 3.2 mg/dl. One patient developed three significant toxicities, including Epstein-Barr virus lymphoproliferative disease (EBV-LPD), severe hemorrhagic cystitis, and transient congestive heart failure (CHF). This patient has been described in detail previously. 22 Bulky cervical and nasopharyngeal lymphomatous disease developed 5 months post BMT. The inflammatory response associated with infiltration of EBVspecific cytotoxic T-lymphocytes (CTLs) resulted in airway obstruction and mucosal sloughing, requiring tracheostomy. During this acute life-threatening illness, this patient also experienced grade III hemorrhagic cystitis requiring temporary suprapubic catheter placement. EBV DNA was isolated from cystoscopy washings. During the episode of hemorrhagic cystitis, the patient developed transient grade II congestive heart failure (CHF) requiring treatment with digoxin. The etiology of the CHF was presumed to be fluid overload. The EBV-LPD completely resolved with two treatment courses of EBV-specific cytotoxic T-lymphocytes. These complications resolved completely in all three patients. Chimerism analyses done after transplantation revealed 100% donor-derived hematopoiesis in bone marrow samples from all three patients at multiple time points after BMT. No patient had a period of mixed hematopoietic chimerism. All patients are alive and well at a median follow-up of 3 years (range, 2.5-5.1 years), with no evidence of recurrence of aplastic anemia, MDS, or PNH.
Discussion
Correction of the hematologic manifestations of PNH by transplantation of syngeneic and genotypically matched bone marrow has been previously demonstrated. ExperiBone Marrow Transplantation ence suggests a relatively high rate of graft failure with the use of non-conditioned transplants. Endo et al 16 reported transient correction of clinical manifestations of PNH associated with an increase in normal donor cells with normal GPI-anchored proteins in a patient with a history of recurrent hemoglobinuria and chest pain. The patient remained asymptomatic for 13 months, but subsequently experienced recurrent symptoms and progressive dominance of hematopoiesis by GPI-anchored protein-deficient stem cells. This report suggested that abnormal PNH cells appeared to have a proliferative advantage over normal syngeneic donor cells.
Bemba et al 13 reported 16 patients with PNH transplanted with matched sibling donors over a 20-year period at the Hospital Saint-Louis. Six patients developed PNH after therapy for aplastic anemia while 10 had de novo PNH. Of the 10 de novo cases, six had prior therapy with androgens or anti-lymphocyte globulin. Four had evidence of alloimmunization. All patients engrafted after receiving pretransplant conditioning followed by a median of 2.6 ϫ 10 8 nucleated cells/kg. Grade II-III acute GVHD occurred in eight patients, while three developed chronic GVHD. The 5-year survival rate was 58%, with seven deaths from GVHD and/or infection. GVHD morbidity and mortality was relatively high, perhaps related to single agent prophylaxis for GVHD.
Saso et al 14 reported the outcome of 57 patients reported to the International Bone Marrow Transplant Registry (IBMTR). Patients were transplanted between 1978 and 1995. Forty-nine patients were transfused pre-BMT with a median of 40 units (range, 1-300). Conditioning regimens were variable but most often included busulfan/ cyclophosphamide or cyclophosphamide/irradiation. Two patients received syngeneic BMT while 48 received HLAmatched sibling donor BMT and seven received alternate donor (six matched unrelated donor, one phenotypically matched family member) BMT. Donor engraftment occurred in only 77%. Both recipients of syngeneic BMT had successful transplants, while 58% of matched sibling donor BMT recipients were alive at 2 years. Only one of seven alternate donor recipients survived the procedure. A substantial proportion of patients, 34% and 33%, respectively, developed grade II-IV acute GVHD or chronic GVHD. Deaths occurred due to graft failure (n = 7), interstitial pneumonitis (IP) (n = 4), GVHD (n = 3), infection (n = 3), adult respiratory distress syndrome (n = 2), and hemorrhage (n = 1). In alternate donors, there were six deaths from graft failure (n = 2), IP (n = 1), organ failure (n = 1), chronic GVHD (n = 1), and malignancy (n = 1).
In our series of three heavily pre-treated, heavily transfused patients, full donor engraftment was achieved. Reports of BMT with unrelated and haploidentical donors have shown successful engraftment is achievable despite large numbers of prior transfusions. 23, 24 In a report by Davies et al 23 primary engraftment occurred in six of seven patients despite extensive red cell transfusions and platelet refractoriness prior to BMT. Tzeng et al 24 reported successful engraftment in six consecutive patients despite a median of 13 units of red blood cells and a median of 39 units of platelets received before BMT. Full donor engraftment was achieved in our three patients despite extensive red blood cell and platelet exposure before BMT.
Although the mortality rate was high in the previous report of alternative donor BMT for patients with PNH, the three patients in this report have had successful outcomes after BMT. We have previously reported equivalent outcome of BMT with MSD or matched unrelated donors for children with leukemia. 20 After in vitro T cell depletion of unrelated donor grafts with anti-CD6/CD8 monoclonal antibodies ϩ complement followed by cyclosporine prophylaxis, one patient experienced transient grade 1 acute GVHD and none developed chronic GVHD. These three patients experienced other transplant-related complications including hemorrhagic cystitis, hemolytic-uremic syndrome, and EBV-LPD. Despite the BMT-related complications requiring therapeutic intervention, our patients have recovered uneventfully and remain free of aplastic anemia and MDS after 30-62 months of follow-up. These results support the cautious use of T cell-depleted unrelated-donor BMT for patients with PNH-related disease processes, such as SAA or MDS. In this series, the use of extensive blood products before BMT was not associated with alloimmunization or graft failure.
Future strategies should include more immunosuppressive, less myelobalative conditioning to lessen toxicity. This strategy could be strengthened by the infusion of large doses of highly purified CD34 ϩ cells to overcome resistance to engraftment and prevent severe GVHD. CD34 selection may also lessen the risk of EBV-LPD that is associated with antibody-based methods of T-cell depletion. The relationship between reduced-intensity conditioning, large doses of highly purified CD34 ϩ cells, and eradication of the patient's abnormal PNH clone would be an area of worthy further investigation.
